,address1,address2,city,state,zip,country,phone,fax,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Rialto South Tower,Level 23 525 Collins Street 201 Sussex Street,Melbourne,VIC,3000,Australia,61 3 8689 9997,61 3 9602 4709,https://www.lctglobal.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.","{'maxAge': 1, 'name': 'Mr. David Richard Hainsworth', 'age': 49, 'title': 'CEO & Exec. Chairman', 'yearBorn': 1973, 'fiscalYear': 2023, 'totalPay': 40000, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.0,0.478978,452397,452397,1214754,584046,584046,0.014,0.015,0,0,22899102,0.008,0.018,545.0091,0.01509,0.01223505,0.0,0.0,AUD,18787976,0.0,1123263843,1635650048,0.28458,0.0,1635650048,0.002,7.0,1688083200,1719705600,1688083200,-2107658,-0.0,447.162,-14.828,0.038461566,0.14113986,ASX,EQUITY,LCT.AX,LCT.AX,ALGORAE PHARMACEUTICALS LTD,Living Cell Technologies Limited,1093996800,Australia/Sydney,AEST,13030029-4739-375d-bd11-8e84dc38ea77,finmb_11941958,36000000,0.014,none,4111074,0.003,-1267052,0,9.352,9.352,42016,0.0,-0.18672001,-0.54064,42016,-648551,-1986291,11.336,1.0,0.0,-30.169079,AUD,
1,Rialto South Tower,Level 23 525 Collins Street 201 Sussex Street,Melbourne,VIC,3000,Australia,61 3 8689 9997,61 3 9602 4709,https://www.lctglobal.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.","{'maxAge': 1, 'name': 'Mr. Daya  Uka', 'title': 'Chief Financial Officer', 'fiscalYear': 2023, 'totalPay': 153082, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.0,0.478978,452397,452397,1214754,584046,584046,0.014,0.015,0,0,22899102,0.008,0.018,545.0091,0.01509,0.01223505,0.0,0.0,AUD,18787976,0.0,1123263843,1635650048,0.28458,0.0,1635650048,0.002,7.0,1688083200,1719705600,1688083200,-2107658,-0.0,447.162,-14.828,0.038461566,0.14113986,ASX,EQUITY,LCT.AX,LCT.AX,ALGORAE PHARMACEUTICALS LTD,Living Cell Technologies Limited,1093996800,Australia/Sydney,AEST,13030029-4739-375d-bd11-8e84dc38ea77,finmb_11941958,36000000,0.014,none,4111074,0.003,-1267052,0,9.352,9.352,42016,0.0,-0.18672001,-0.54064,42016,-648551,-1986291,11.336,1.0,0.0,-30.169079,AUD,
2,Rialto South Tower,Level 23 525 Collins Street 201 Sussex Street,Melbourne,VIC,3000,Australia,61 3 8689 9997,61 3 9602 4709,https://www.lctglobal.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.","{'maxAge': 1, 'name': 'Dr. Belinda Di Bartolo', 'title': 'Chief Operations Officer', 'fiscalYear': 2023, 'totalPay': 182328, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.0,0.478978,452397,452397,1214754,584046,584046,0.014,0.015,0,0,22899102,0.008,0.018,545.0091,0.01509,0.01223505,0.0,0.0,AUD,18787976,0.0,1123263843,1635650048,0.28458,0.0,1635650048,0.002,7.0,1688083200,1719705600,1688083200,-2107658,-0.0,447.162,-14.828,0.038461566,0.14113986,ASX,EQUITY,LCT.AX,LCT.AX,ALGORAE PHARMACEUTICALS LTD,Living Cell Technologies Limited,1093996800,Australia/Sydney,AEST,13030029-4739-375d-bd11-8e84dc38ea77,finmb_11941958,36000000,0.014,none,4111074,0.003,-1267052,0,9.352,9.352,42016,0.0,-0.18672001,-0.54064,42016,-648551,-1986291,11.336,1.0,0.0,-30.169079,AUD,
3,Rialto South Tower,Level 23 525 Collins Street 201 Sussex Street,Melbourne,VIC,3000,Australia,61 3 8689 9997,61 3 9602 4709,https://www.lctglobal.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.","{'maxAge': 1, 'name': 'Dr. Carolyn M. Sue A.M., B.S., Ph.D.', 'age': 59, 'title': 'Member of Medical Advisory Board & Chief Medical Officer of NTCELL', 'yearBorn': 1963, 'fiscalYear': 2023, 'totalPay': 50000, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.0,0.478978,452397,452397,1214754,584046,584046,0.014,0.015,0,0,22899102,0.008,0.018,545.0091,0.01509,0.01223505,0.0,0.0,AUD,18787976,0.0,1123263843,1635650048,0.28458,0.0,1635650048,0.002,7.0,1688083200,1719705600,1688083200,-2107658,-0.0,447.162,-14.828,0.038461566,0.14113986,ASX,EQUITY,LCT.AX,LCT.AX,ALGORAE PHARMACEUTICALS LTD,Living Cell Technologies Limited,1093996800,Australia/Sydney,AEST,13030029-4739-375d-bd11-8e84dc38ea77,finmb_11941958,36000000,0.014,none,4111074,0.003,-1267052,0,9.352,9.352,42016,0.0,-0.18672001,-0.54064,42016,-648551,-1986291,11.336,1.0,0.0,-30.169079,AUD,
4,Rialto South Tower,Level 23 525 Collins Street 201 Sussex Street,Melbourne,VIC,3000,Australia,61 3 8689 9997,61 3 9602 4709,https://www.lctglobal.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.","{'maxAge': 1, 'name': 'Mr. Madhukar  Bhalla FCIS', 'age': 63, 'title': 'Company Sec.', 'yearBorn': 1959, 'fiscalYear': 2023, 'totalPay': 40000, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.0,0.478978,452397,452397,1214754,584046,584046,0.014,0.015,0,0,22899102,0.008,0.018,545.0091,0.01509,0.01223505,0.0,0.0,AUD,18787976,0.0,1123263843,1635650048,0.28458,0.0,1635650048,0.002,7.0,1688083200,1719705600,1688083200,-2107658,-0.0,447.162,-14.828,0.038461566,0.14113986,ASX,EQUITY,LCT.AX,LCT.AX,ALGORAE PHARMACEUTICALS LTD,Living Cell Technologies Limited,1093996800,Australia/Sydney,AEST,13030029-4739-375d-bd11-8e84dc38ea77,finmb_11941958,36000000,0.014,none,4111074,0.003,-1267052,0,9.352,9.352,42016,0.0,-0.18672001,-0.54064,42016,-648551,-1986291,11.336,1.0,0.0,-30.169079,AUD,
5,Rialto South Tower,Level 23 525 Collins Street 201 Sussex Street,Melbourne,VIC,3000,Australia,61 3 8689 9997,61 3 9602 4709,https://www.lctglobal.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.","{'maxAge': 1, 'name': 'Dr. James A. Mckenna', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.014,0.0,0.478978,452397,452397,1214754,584046,584046,0.014,0.015,0,0,22899102,0.008,0.018,545.0091,0.01509,0.01223505,0.0,0.0,AUD,18787976,0.0,1123263843,1635650048,0.28458,0.0,1635650048,0.002,7.0,1688083200,1719705600,1688083200,-2107658,-0.0,447.162,-14.828,0.038461566,0.14113986,ASX,EQUITY,LCT.AX,LCT.AX,ALGORAE PHARMACEUTICALS LTD,Living Cell Technologies Limited,1093996800,Australia/Sydney,AEST,13030029-4739-375d-bd11-8e84dc38ea77,finmb_11941958,36000000,0.014,none,4111074,0.003,-1267052,0,9.352,9.352,42016,0.0,-0.18672001,-0.54064,42016,-648551,-1986291,11.336,1.0,0.0,-30.169079,AUD,
